GC Pharma & Clinigen KK partnership to commercialise Hunter syndrome drug in Japan.

Global Banking News-April 4, 2019-GC Pharma & Clinigen KK partnership to commercialise Hunter syndrome drug in Japan

(C)2019 ENPublishing - http://www.enpublishing.co.uk

South Korean biopharmaceutical company GC Pharma (KRX:006280) disclosed on Wednesday that it plans to commercialise Hunterase (Idursulfase-beta) ICV for the treatment of Hunter syndrome in Japan under an exclusive licensing agreement with Clinigen KK, a wholly owned subsidiary of Clinigen Group plc (LON:CLIN).

Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disease that occurs primarily in boys. It causes an enzyme deficiency that interferes with the body's ability to break down certain complex sugars, resulting in serious skeletal, tissue, neurological and multi-organ complications and ultimately, death.

GC Pharma's Hunterase (Idursulfase-beta) ICV is a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy. The intravenous injection does not penetrate the blood-brain barrier in clinically...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT